HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from the platform after accusing the company of selling “illegitimate, knockoff ...

University of Florida researchers said a new study could lead to a universal cancer shot, while digital health earnings ...

If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

Marketers need to choose brand partners wisely in order to avoid messy splits under the eye of a consumer who is more ...

Fangzhou has signed a MoU with Novo Nordisk to collaborate on the management of serious chronic diseases, including obesity and diabetes.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.